Tibet Rhodiola Pharmaceutical Holding Co.,Ltd.’s Net Profit Rose 6% in First Three Quarters of 2022

Tibet Rhodiola Pharmaceutical Holding Co.,Ltd. (西藏诺迪康药业股份有限公司) (600211.SH) reported a net profit of 447 million yuan in the first three quarters of 2022, up 6% year-on-year.

Meanwhile, the company posted 2 billion yuan in revenue, up 25.4% year-on-year.

At the end of the reporting period, it had 4.3 billion yuan in total assets and 1.2 billion yuan in total liabilities, with a liability-to-asset ratio of 27.8%.